

## Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Therapy for Mantle Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes was observed in the Phase III SHINE trial of ibrutinib in combination with bendamustine/rituximab (BR) and maintenance rituximab as a first-line treatment for older patients with mantle cell lymphoma (MCL)?**
  - The combination of ibrutinib with BR led to a significant improvement in progression-free survival (PFS) and overall survival (OS), compared to control
  - The combination of ibrutinib with BR led to a significant improvement in PFS but not OS, compared to control
  - The combination of ibrutinib with BR did not lead to a significant improvement in PFS or OS, compared to control
- 2. The Phase III TRIANGLE trial evaluating autologous stem cell transplant (ASCT) with ibrutinib versus ibrutinib alone after ibrutinib/rituximab/cytarabine-containing induction therapy in younger patients with mantle cell lymphoma demonstrated which of the following outcomes?**
  - Failure-free survival when ibrutinib was added to ASCT appeared to be superior compared to when ibrutinib was given alone
  - Failure-free survival when ibrutinib was given alone appeared to be superior compared to when ibrutinib was added to ASCT
  - There appeared to be no difference in failure-free survival observed when ibrutinib was added to ASCT versus when ibrutinib was given alone
- 3. A Phase Ib trial evaluating acalabrutinib with venetoclax and rituximab for treatment-naïve MCL demonstrated which of the following outcomes, in terms of overall response rate (ORR)?**
  - A high ORR, with a majority of patients achieving a complete response
  - A high ORR, with a minority of patients achieving a complete response
  - A low ORR, with a minority of patients achieving a complete response
- 4. Which of the following Bruton tyrosine kinase (BTK) inhibitors is able to bind reversibly to its target?**
  - Acalabrutinib
  - Ibrutinib
  - Pirtobrutinib
  - Zanubrutinib
- 5. Updated data from the Phase I/II BRUIN study evaluating pirtobrutinib for previously treated MCL demonstrated which of the following outcomes?**
  - Only patients who were BTK-naïve exhibited tumor responses to pirtobrutinib
  - Only patients who were previously treated with a BTK inhibitor exhibited tumor responses to pirtobrutinib
  - Patients who were BTK-naïve and patients who were previously treated with a BTK inhibitor exhibited tumor responses to pirtobrutinib